Ha Jihyun, Choi Yunha, Jung Mo Kyung, Yoo Eun-Gyong, Yoo Han-Wook
Department of Pediatrics, Bundang CHA Medical Center, CHA University, Seongnam, Korea.
Ann Pediatr Endocrinol Metab. 2024 Feb;29(1):60-66. doi: 10.6065/apem.2346042.021. Epub 2024 Feb 29.
Familial male-limited precocious puberty (FMPP) is a rare form of gonadotropin-independent precocious puberty that is caused by an activating mutation of the LHCGR gene. Herein, we report a case of FMPP with a mutation of the LHCGR gene in a Korean boy with familial history of precocious puberty through 3 generations. A 16-month-old boy presented with signs of precocious puberty, including pubic hair, acne, and increased growth velocity. The patient's grandfather and father had a history of precocious puberty and profound short stature. On physical examination, the patient had prepubertal testes with pubic hair development appropriate for Tanner stage II. The stretched penile length was 7 cm (>2 standard deviation score), and observed bone age was that of a 4-year-old boy. Laboratory findings showed high serum testosterone (5.74 ng/mL [appropriate for Tanner IV-V]; normal range, <0.05 ng/mL) with suppressed luteinizing hormone (<0.07 mIU/mL) and normal serum level of follicular stimulating hormone (0.56 mIU/mL; normal range, 0.38-1.11 mIU/mL). Genetic testing revealed a pathogenic variant of LHCGR (c.1730 C>T (p.Thr577Ileu)), confirming FMPP. Bicalutamide and anastrozole were administered, and pubertal progression was sufficiently suppressed without any specific side effects. To our knowledge, this is the first case of genetically confirmed FMPP in Korea.
家族性男性限性性早熟(FMPP)是一种罕见的促性腺激素非依赖性性早熟,由黄体生成素/绒毛膜促性腺激素受体(LHCGR)基因的激活突变引起。在此,我们报告一例有三代性早熟家族史的韩国男孩发生LHCGR基因突变的FMPP病例。一名16个月大的男孩出现性早熟迹象,包括阴毛、痤疮和生长速度加快。患者的祖父和父亲有性早熟和严重身材矮小的病史。体格检查发现,患者睾丸处于青春期前,阴毛发育符合坦纳II期。阴茎拉伸长度为7厘米(>2标准差评分),观察到的骨龄为4岁男孩的骨龄。实验室检查结果显示血清睾酮水平高(5.74纳克/毫升[符合坦纳IV - V期];正常范围,<0.05纳克/毫升),黄体生成素水平受抑制(<0.07毫国际单位/毫升),血清卵泡刺激素水平正常(0.56毫国际单位/毫升;正常范围,0.38 - 1.11毫国际单位/毫升)。基因检测发现LHCGR的一个致病变异(c.1730 C>T(p.Thr577Ileu)),确诊为FMPP。给予比卡鲁胺和阿那曲唑治疗,青春期进展得到充分抑制,且无任何特定副作用。据我们所知,这是韩国首例经基因确诊的FMPP病例。